|Mr. John C. London LLB, LLM||Chief Exec. Officer and Director||555.62k||N/A||N/A|
|Mr. Jesse F. Ledger||Pres||217.36k||N/A||N/A|
|Ms. Mary-Jane E. Burkett CPA-CA, HBA||Chief Financial Officer, VP and Corp. Controller||193.63k||N/A||N/A|
|Mr. Calogero Lunetta MSc||VP of Manufacturing||338.67k||N/A||N/A|
|Dr. Bernard Joseph Chiasson Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Nuvo Pharmaceuticals Inc., a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; and Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.
Nuvo Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.